Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COSTAN
- Sponsors Biogen
- 28 Jan 2016 Last checked against ClinicalTrials.gov record.
- 26 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 22 Feb 2015 Modified the official title, inclusion and exclusion criteria as per ClinicalTrials.gov record.